Myriad Genetics and Flatiron Health Collaborate to Expand Access to Genetic Testing Through EMR Integration

QIAGEN and Illumina Unveil New Solutions to Advance Liquid Biopsy and Next-Generation Sequencing

The Role of Biobanks in Advancing Precision Medicine

AstraZeneca and Daiichi Sankyo's Enhertu Secures Conditional Approval in China for HER2-Mutated NSCLC Treatment

SkylineDx Presents Breakthrough Data from Largest Melanoma Genomic Assay Trial at SMR Annual Meeting

Clario and PathAI Join Forces to Streamline GI Clinical Trials with Integrated Solutions

FDA Approves FoundationOne® Liquid CDx as Companion Diagnostic for Itovebi™ (inavolisib) to Identify Hormone Receptor-Positive, HER2-Negative Breast Cancer Patients with PIK3CA Mutation

Roche’s VENTANA CLDN18 (43-14A) RxDx Assay for Identifying Gastric and GEJ Cancer Patients Receives CE Mark Approval

Tempest and Roche Partner to Advance Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Singapore to Expand MediShield Life Coverage for Precision Medicine and Strengthen Genetic Data Protections

Bayer and MOMA Therapeutics Partner to Advance Precision Oncology Therapies

DermTech's Non-Invasive Genomic Testing Shows Promise in Differentiating Melanoma from Atypical Moles

Velsera and Diagnostic Longwood Partner to Accelerate Precision Medicine in Spain and Portugal

Aurigene Oncology Reports Promising Phase 1 Results for India’s First CAR-T Cell Therapy in Multiple Myeloma

Agilus Diagnostics Launches Pharmacogenomics Testing Service to Revolutionize Personalized Medicine

Home
/
insight
/
details

Impact of Proteomics on Personalized Medicine and Treatment Monitoring

NextEdge Admin

20 Jun 2024

3 min 18 sec

Personalized Medicine,mass spectrometry,microfluidics

Proteomics has fundamentally transformed cancer diagnostics and treatment monitoring by focusing on the study of proteins and their roles within biological systems. Unlike traditional methods such as imaging and biopsies, which can be invasive and prone to errors, proteomic technologies offer precise advantages through the detection of specific protein biomarkers.

A cornerstone of proteomics in cancer lies in its capability to enhance early detection and prognosis assessment. Techniques like enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), and flow cytometry enable the identification of proteomic patterns that facilitate the diagnosis of cancer at earlier stages. For instance, cancer antigen 125 (CA-125) is widely employed to monitor ovarian cancer progression, while prostate-specific antigen (PSA) aids in the early detection of prostate cancer.

Advanced proteomic methods such as mass spectrometry, protein arrays, and microfluidics play pivotal roles in advancing cancer diagnosis and personalized treatment strategies. These technologies empower researchers and clinicians to analyze intricate protein interactions, post-translational modifications, and expression profiles specific to different cancer types. Mass spectrometry, with its capability to identify and quantify proteins even in minute amounts, is invaluable for unraveling cancer biology and identifying potential therapeutic targets.

Proteins like PSA for prostate cancer, CA-125 for ovarian cancer, and CEA for colorectal cancer are routinely assessed using ELISA and IHC, providing critical diagnostic and prognostic information. Furthermore, proteins such as HER2 in breast cancer, BRCA1/2 involved in genetic predisposition to breast and ovarian cancers, and Ki-67 as a marker of cell proliferation are analyzed through immunohistochemistry, guiding treatment decisions and patient management strategies. Additionally, proteins like EGFR in lung cancer are evaluated to determine eligibility for targeted therapies, showcasing how proteomic analyses facilitate personalized medicine approaches tailored to individual patient needs.

Moreover, proteomic analyses offer insights into disease progression and treatment responses by monitoring changes in protein biomarkers over time. This enables clinicians to tailor therapies more precisely and evaluate their effectiveness. This approach not only improves patient outcomes by enabling timely interventions but also enhances healthcare efficiency by reducing unnecessary procedures.